Compare IDYA & NATL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IDYA | NATL |
|---|---|---|
| Founded | 2015 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.3B |
| IPO Year | 2019 | 2023 |
| Metric | IDYA | NATL |
|---|---|---|
| Price | $27.99 | $45.03 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 4 |
| Target Price | ★ $52.86 | $45.60 |
| AVG Volume (30 Days) | ★ 1.4M | 724.6K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 61.90 | ★ 73.98 |
| EPS | N/A | ★ 0.29 |
| Revenue | $218,710,000.00 | ★ $4,354,000,000.00 |
| Revenue This Year | N/A | $6.13 |
| Revenue Next Year | $201.05 | $4.24 |
| P/E Ratio | ★ N/A | $151.17 |
| Revenue Growth | ★ 3024.43 | 0.86 |
| 52 Week Low | $17.17 | $23.56 |
| 52 Week High | $39.28 | $48.50 |
| Indicator | IDYA | NATL |
|---|---|---|
| Relative Strength Index (RSI) | 36.30 | 55.64 |
| Support Level | $26.05 | $42.20 |
| Resistance Level | $28.05 | $46.29 |
| Average True Range (ATR) | 1.15 | 0.93 |
| MACD | -0.12 | -0.07 |
| Stochastic Oscillator | 7.68 | 57.25 |
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
NCR Atleos Corp is a financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers, and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels, all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware, and its proprietary Allpoint network. Atleos manages its operations in the following segments: Self-Service Banking, which generates maximum revenue, Network, and Telecommunications and Technology. Geographically, it derives maximum revenue from the U.S.